1019 ET - Hims & Hers Health is still benefiting from the fact that consumers are struggling to obtain branded weight-loss drugs, known as GLP-1s, TD Cowen analysts say in a research note. The stock has been volatile due to uncertainty around whether Hims can keep offering its compounded GLP-1 after a shortage of branded GLP-1s was resolved, the analysts say. But the environment for GLP-1s is still highly dynamic and Hims' compounded version is still a credible solution for consumers that can't easily get branded GLP-1s, the analysts say. That said, the risk remains that regulators could swoop in at some point with new restrictions around compounded drugs, the analysts say. (dean.seal@wsj.com)
(END) Dow Jones Newswires
November 05, 2024 10:19 ET (15:19 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.